Gm-Csf
Neoplasms, Liver
Lisa H. Butterfield, Ph.D.Phase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Neoplasms, Liver cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Pexastimogene Devacirepvec Jennerex Biotherapeutics | Phase 1 | CC |
Gm-Csf, Sargramostim Jennerex Biotherapeutics | Phase 1 | CC |
Same molecule, other indications
Gm-Csf is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →